double-skinned crabsVietnamese crab exporter
Advertisement
Advertisement
TOPIC

Biomedicine: Geopolitics

Biomedicine: Geopolitics
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Chinese antibody-drug conjugates, which deliver drugs directly to tumour cells, helped show China's innovative capabilities, according to an analyst. Photo: Shutterstock Images
Biomedicine: Industry Trends

Chinese drug sector’s stature grows at major cancer conference

Hansoh Pharmaceutical, Akeso and others tout positive results as Chinese research accounts for larger percentage of presentations.

videocam
Accounting and auditing

China’s Hengrui surges in Hong Kong after 89% rise in third-quarter net profit

videocam
China’s private sector

Chinese biotech giant WuXi AppTec raises 2026 outlook after profit surge

Biomedicine: Industry Trends

Could new US investment curbs complicate China’s biotech licensing surge?

Licensing deals untouched for now, but proposed US investment rules and new Chinese export curbs may impact biotech expansion, analysts say.

Chinese firms have assumed a growing role in the global biopharmaceutical industry in recent years. Photo: Shutterstock
Biomedicine: Industry Trends

China takes step to standardise technology linking human minds to computers

As Beijing prioritises development of the technology, a China-led committee aims to dictate how it is built.

Science

China is a beacon of global embryo research, says scientist after return from US

Wu Jun joins Hangzhou’s Westlake University to advance organ regeneration and AI-driven embryo research.

videocam
16
Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

Hong Kong needs new funding model to attract global drug makers: AstraZeneca

The pharmaceutical giant has conducted more than 60 clinical trials worth US$25.5 million in the city over the last three years.

videocam
David Fredrickson, executive vice-president of oncology business at AstraZeneca. Photo: Jonathan Wong
China technology

Chinese biopharma’s global expansion

Chinese developers of innovative drugs are tying up with industry giants to accelerate overseas growth, raise funds and share risks.

China technology

Are clinical trials about to become a new front in the US-China biotech race?

China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned.

Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
Employees work at a Fosun Pharmaceuticals facility in Shanghai. Photo: Handout
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

Industry leaders highlight city’s international reach and expertise as state-owned drug maker considers Northern Metropolis project investment.

A general view of Guangzhou. The Hong Kong and Macau Affairs Office arranged a six-day trip spanning the Greater Bay Area. Photo: Eugene Lee
China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

China economy

Outside In | China’s export success is a by-product of self-reliance

But while the export surge is an accidental consequence of self-sufficiency and competitive manufacturers, the solution is not protectionism.

videocam
7
Containers sitting stacked at the Port of Shanghai on July 14 in China. Photo: VCG via Getty Images
Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
Scientists in the biotech sector fear China will impose restrictive regulations after a child died in a gene-editing trial in 2025. Photo: Shutterstock
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

Advertisement
Advertisement
Advertisement
China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
In addition to surging novel drug development, China’s cross-border deals with global giants show no sign of abating. Photo: Shutterstock
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.

China manufacturing

The next rare earths? Why US fears another Chinese manufacturing advantage

China’s production of drug inputs has boomed in recent years, increasing market share and prompting fears of weaponisation in Washington.

videocam
26
US-China relations

US National Science Foundation to ban projects with flagged Chinese institutions

Raising security fears, NSF moves from case-by-case approval to full ban on working with restricted entities and their employees.

The US National Science Foundation is moving away from Chinese collaborators that have been flagged as restricted entities by the government. Photo: Shutterstock
China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Chinese biotech and innovative drug firms are rapidly closing the gap with its US rivals as it continues to develop RAS-targeted cancer therapies. Photo: Shutterstock
China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Medicine

China closing in but US leads in biotech quality and commercial reach: survey

The Cure survey said China leads ⁠in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

videocam
A scientist works with a microscope and test tubes in a research laboratory. Photo: Shutterstock
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement